Faecalibacterium prausnitzii Is Associated With Clinical Response to Immune Checkpoint Inhibitors in Patients With Advanced Gastric Adenocarcinoma: Results of Microbiota Analysis of PRODIGE 59-FFCD 1707-DURIGAST Trial
Marius Bredon, Karine le Malicot, Christophe Louvet, Ludovic Evesque, Daniel Gonzalez, David Tougeron, Harry Sokol
Abstract
International audience
Topics & Concepts
Faecalibacterium prausnitziiMedicineInternal medicineGastroenterologyAdenocarcinomaOncologyGut floraImmunologyCancerColorectal Cancer Treatments and StudiesGastric Cancer Management and OutcomesMycobacterium research and diagnosis